Ann: PTX unveils new clinic-ready CAR-T enhancement platform, page-59

CellPryme-M = Manufacture (Improvement)

CellPryme-A = ?? My guess is Allogeneic T-Cells (off the shelf cells) from healthy volunteers rather than the 3 week delay from developing one's own cells for the OmniCAR treatment of a specific cancer.

In having drum loads of cells for immediate use for many patients rather than the hundreds/thousands of individual processes to have small cell quantities, would make the price of treatment more realistic, controllable and less a logistic nightmare.

The only downside would be the safety/compatibility issues that could take time to overcome/gain approval.

I understand that there are a few companies nearing trials for a variety of purposes - not necessarily oncology.

This is the only deficiency in the PTX package to have a completely integrated approach to the future - where in a decade, one may be identified with a potentially curable cancer one day and within a week be in a local infusion room with a local oncologist receiving your treatment.

The next few months will be interesting - the next 2.5 years potentially exciting.

I may get back to a buy sentiment sooner than expected.